文献速递炎症性肠病

克罗恩病中的排便急迫感:米吉珠单抗在随机对照3期研究中的效果

Bowel Urgency in Crohn's Disease: Effects of Mirikizumab in a Randomized Controlled Phase 3 Study.
PubMed 文献 · Clin Gastroenterol Hepatol · 2025-07-14

VIVID-1三期研究纳入成人克罗恩病患者,随机接受米吉珠单抗或安慰剂,用急迫感数字评定量表(NRS)评估排便急迫感(BU)。基线94.2%患者NRS≥3,米吉珠单抗组从第6周起BU改善显著优于安慰剂并持续至第52周,第12周和第52周BU临床意义改善和缓解率均显著更高,且与更好的临床和内镜结局相关。

要点

  • 基线时94.2%的克罗恩病患者急迫感NRS评分≥3。
  • 米吉珠单抗组BU改善从第6周起显著优于安慰剂,持续至第52周。
  • 第12周达到BU临床意义改善者第12周和第52周临床及内镜结局更好。

核心结论

  • 米吉珠单抗治疗组在第12周和第52周达到BU临床意义改善和缓解的比例显著高于安慰剂组,且与更好的短期和长期临床结局相关。

研究设计与样本

  • VIVID-1是一项3期随机对照研究,成人参与者随机接受米吉珠单抗或安慰剂治疗。
  • BU采用急迫感数字评定量表(NRS,范围0-10)在基线和每4周评估。

主要发现

  • 基线时94.2%的参与者急迫感NRS评分≥3。
  • BU与克罗恩病活动指数和腹痛呈正相关。
  • 米吉珠单抗组从第6周起BU较基线的改善显著大于安慰剂组,并持续至第52周。
  • 米吉珠单抗组第12周和第52周的BU临床意义改善率和BU缓解率均显著高于安慰剂组。
  • 第12周达到BU临床意义改善的米吉珠单抗治疗参与者在第12周和第52周有更好的临床和内镜结局。

关键数值与推荐

  • BU临床意义改善定义为急迫感NRS变化≥3分。
  • BU缓解定义为急迫感NRS≤2分。
  • 基线急迫感NRS≥3和≥6的参与者比例被计算。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Bowel urgency (BU) is an underrecognized and debilitating symptom of Crohn's disease. Mirikizumab, an interleukin-23p19 inhibitor, is efficacious for BU resolution in ulcerative colitis. We evaluated the efficacy of mirikizumab in achieving early BU response and remission among participants with Crohn's disease enrolled in the phase 3 VIVID-1 study. The associations of disease characteristics with baseline BU and BU resolution were explored. METHODS: Adult participants were randomized to receive mirikizumab or placebo. BU was assessed using the Urgency Numeric Rating Scale (NRS) (range 0-10) at baseline, and every 4 weeks. The proportion of participants with baseline Urgency NRS ≥3 and ≥6 who achieved BU clinically meaningful improvement (CMI) (≥3 change in Urgency NRS) and BU remission (Urgency NRS ≤2) was calculated, and associations of BU CMI and BU remission with clinical outcomes were assessed. RESULTS: At baseline, 94.2% of participants had an Urgency NRS score ≥3. BU positively correlated with the Crohn's Disease Activity Index and abdominal pain. Improvement in BU from baseline was significantly greater in mirikizumab-treated participants as early as week 6 and sustained to week 52 vs patients receiving placebo. Participants treated with mirikizumab achieved significantly higher rates of BU CMI and BU remission at weeks 12 and 52 vs placebo. Mirikizumab-treated participants who achieved BU CMI at week 12 had better clinical and endoscopic outcomes at weeks 12 and 52. CONCLUSIONS: Mirikizumab-treated participants achieved significantly higher rates of BU CMI and remission at weeks 12 and 52, which was associated with better short- and longer-term clinical outcomes. CLINICALTRIALS: gov, Number: NCT03926130.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Jairath V, D'Haens G, Sands BE, et al. Bowel Urgency in Crohn's Disease: Effects of Mirikizumab in a Randomized Controlled Phase 3 Study. Clin Gastroenterol Hepatol. 2025. PMID: 40669578. doi:10.1016/j.cgh.2025.07.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。